Restructuring, lawsuits, dividends: what keeps British American Tobacco afloat
Shares of British American Tobacco $BTI traded around $63 per ADR on the New York Stock Exchange in mid-July 2026, roughly a fifth higher than at their spring lows, while the company is simultaneously cutting 9,000 jobs, paying installments on the Canadian lawsuit worth approximately $23.5 billion (C$32.5 billion), and less than three years ago wrote off $31.5 billion in value of US cigarette brands. Yet analysts at banks such as BofA, Jefferies, or UBS give it a buy rating with target prices between $69 and $80 per ADR.
Key points
Cheap valuation vs. competitors. BAT trades at a forward P/E of around 11-12x, significantly below Philip Morris (~22x) and Altria (~12x), with a dividend yield of 5-6%.
Fit2Win as a bet on execution. The 9,000 job cuts are expected to bring ~$793 million in annual savings by 2028, but historically, the risk of delays in similar restructurings has been higher than models project.
Velo is catching up with Zyn, but from second place. Nicotine pouches are growing fastest of all segments, but Zyn still holds a significantly higher US market share and regulatory developments (FDA) can cut both ways.
Canadian and US litigation risk is largely resolved. The C$32.5 billion settlement finally gives the company clarity on costs, even though it will pay them off over years; renewed disputes (Mississippi), however, show that old cases occasionally return.
Debt is falling, capital returns to shareholders. Leverage is heading toward the 2.0-2.5x range by end-2026, the dividend and buyback ($1.8 billion for 2026) run simultaneously, but a large portion of cash flow is already allocated in advance.
A company standing on a long-term shrinking cigarette business is also accelerating in nicotine pouches Velo, catching up with market leader Zyn from Philip Morris $PM, and promising investors to generate over $70 billion in free cash flow by 2030. The combination of a deep restructuring cut, legal settlement of old liabilities, and a new product category makes BAT one of the more interesting dividend stocks this summer, though not without risks.
Fit2Win: what lies behind the 9,000 job cuts
At the end of June 2026, BAT announced that under the Fit2Win program it would eliminate approximately 5,500 jobs worldwide and transfer another 3,500 positions to external partners, primarily to consulting firm Accenture $ACN. Together, the restructuring will affect about 9,000 people, roughly a fifth of the global headcount. The program covers all markets except the United States, which BAT specifically excluded from the restructuring because the US business is undergoing its own transformation around the launch of Velo Plus and defending cigarette market share.
Finish the whole article on ACN
And you also unlock fair value and more tools
Black membership: analyses, screener, newsletters and unlimited StockBot.